Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
FibroGen, Inc. stock logo
FGEN
FibroGen
$0.31
-3.2%
$0.30
$0.18
$1.53
$31.24M0.831.95 million shs1.53 million shs
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
$4.68
+5.2%
$4.22
$3.62
$9.18
$34.19M0.5855,933 shs19,366 shs
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
$0.55
-0.2%
$0.55
$0.22
$1.97
$30.32M1.031.79 million shs260 shs
ObsEva SA stock logo
OBSV
ObsEva
$0.00
$0.08
$2.14
$7.94M0.688.94 million shs15,113 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
FibroGen, Inc. stock logo
FGEN
FibroGen
-3.22%+2.62%+0.39%-32.83%-72.64%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
+5.17%+6.61%+8.33%-20.14%-34.95%
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
0.00%0.00%0.00%0.00%-64.34%
ObsEva SA stock logo
OBSV
ObsEva
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
FibroGen, Inc. stock logo
FGEN
FibroGen
4.2015 of 5 stars
3.32.00.04.72.13.30.6
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
4.2652 of 5 stars
3.25.00.04.60.62.50.6
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
1.9994 of 5 stars
3.20.00.04.20.01.70.6
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
FibroGen, Inc. stock logo
FGEN
FibroGen
2.50
Moderate Buy$10.003,134.15% Upside
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
2.33
Hold$39.50744.02% Upside
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
2.40
Hold$4.79771.56% Upside
ObsEva SA stock logo
OBSV
ObsEva
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest OBSV, KZR, FGEN, and MRNS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2025
FibroGen, Inc. stock logo
FGEN
FibroGen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/1/2025
FibroGen, Inc. stock logo
FGEN
FibroGen
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
3/18/2025
FibroGen, Inc. stock logo
FGEN
FibroGen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
(Data available from 6/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
FibroGen, Inc. stock logo
FGEN
FibroGen
$7.00M4.47N/AN/A($1.87) per share-0.17
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
$7M4.88N/AN/A$25.80 per share0.18
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
$30.99M0.98N/AN/A$0.31 per share1.77
ObsEva SA stock logo
OBSV
ObsEva
$20.11M0.00N/AN/A$0.41 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
FibroGen, Inc. stock logo
FGEN
FibroGen
-$284.23M-$0.10N/AN/AN/A-67.66%N/A-36.17%8/5/2025 (Estimated)
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-$101.87M-$10.82N/AN/AN/AN/A-54.95%-46.11%8/12/2025 (Estimated)
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
-$141.40M-$2.47N/AN/AN/A-446.48%-7,831.35%-120.74%8/11/2025 (Estimated)
ObsEva SA stock logo
OBSV
ObsEva
-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/A

Latest OBSV, KZR, FGEN, and MRNS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-$2.56-$2.27+$0.29-$2.27N/AN/A
5/12/2025Q1 2025
FibroGen, Inc. stock logo
FGEN
FibroGen
$0.03-$0.16-$0.19$0.05$2.00 million$2.70 million
3/25/2025Q4 2024 & Study Result
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-$2.71-$2.77-$0.06-$2.77N/AN/A
3/17/2025Q4 2024
FibroGen, Inc. stock logo
FGEN
FibroGen
-$0.08-$0.08N/A$0.18$24.91 million$3.14 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
FibroGen, Inc. stock logo
FGEN
FibroGen
N/AN/AN/AN/AN/A
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
N/AN/AN/AN/AN/A
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
N/AN/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
FibroGen, Inc. stock logo
FGEN
FibroGen
N/A
1.28
1.16
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
0.05
7.65
7.65
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
N/A
1.66
1.47
ObsEva SA stock logo
OBSV
ObsEva
N/A
0.61
0.61

Institutional Ownership

CompanyInstitutional Ownership
FibroGen, Inc. stock logo
FGEN
FibroGen
72.71%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
67.90%
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
98.80%
ObsEva SA stock logo
OBSV
ObsEva
17.52%

Insider Ownership

CompanyInsider Ownership
FibroGen, Inc. stock logo
FGEN
FibroGen
3.07%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
10.40%
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
5.46%
ObsEva SA stock logo
OBSV
ObsEva
14.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
FibroGen, Inc. stock logo
FGEN
FibroGen
570101.04 million98.78 millionOptionable
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
607.31 million6.62 millionNot Optionable
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
11055.22 million52.20 millionOptionable
ObsEva SA stock logo
OBSV
ObsEva
5077.97 million66.74 millionNot Optionable

Recent News About These Companies

ObsEva Announces Update on Board of Directors
ObsEva SA OBSN
ObsEva SA OBSEF
ObsEva (NASDAQ: OBSV)
ObsEva Annual Report 2022 - Marketscreener.com
ObsEva Annual Report 2022 - Yahoo Finance
ObsEva Annual Report 2022 - Benzinga
ObsEva Annual Report 2022 - EIN News

New MarketBeat Followers Over Time

Media Sentiment Over Time

FibroGen stock logo

FibroGen NASDAQ:FGEN

$0.31 -0.01 (-3.22%)
Closing price 06/10/2025 04:00 PM Eastern
Extended Trading
$0.31 0.00 (-0.71%)
As of 04:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Kezar Life Sciences stock logo

Kezar Life Sciences NASDAQ:KZR

$4.68 +0.23 (+5.17%)
Closing price 06/10/2025 04:00 PM Eastern
Extended Trading
$4.70 +0.03 (+0.53%)
As of 06/10/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Marinus Pharmaceuticals stock logo

Marinus Pharmaceuticals NASDAQ:MRNS

$0.55 0.00 (-0.16%)
As of 02/11/2025

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

ObsEva stock logo

ObsEva NASDAQ:OBSV

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.